Novem Group
UTHR icon

Novem Group’s United Therapeutics UTHR Stock Holding History

Novem Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.1M Buy
2,035
+69
+4% +$35.7K 0.11% 171
2026
Q2 		$1.07M Sell
1,966
-357
-15% -$201K 0.11% 172
2026
Q1 		$1.38M Buy
2,323
+93
+4% +$46.3K 0.16% 119
2025
Q4 		$1.09M Buy
+2,230
New +$1.04M 0.12% 155

Other funds holding UTHR

AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Atwood & Palmer
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Polaris Capital Management
Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Livforsakringsbolaget Skandia
Livforsakringsbolaget Skandia Stockholm, Sweden $3.02B AUM 43.19% 1-Year Est. Return
Nepsis Inc
Nepsis Inc Minneapolis, Minnesota $317M AUM 37.22% 1-Year Est. Return

Novem Group's UTHR Position: Q3 2026 in Review

Novem Group increased its United Therapeutics (UTHR) stake by 3.5% in Q3 2026, buying an estimated $35.7K and bringing the position to 2,035 shares worth $1.1M. The position accounts for 0.11% of the portfolio, ranked #171.

Novem Group first reported a position in UTHR in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.38M in Q1 2026. 180 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Novem Group held 2,035 shares of United Therapeutics worth $1.1M as of Q3 2026.
  • Novem Group bought 69 United Therapeutics shares in Q3 2026, an estimated $35.7K.
  • United Therapeutics made up 0.11% of Novem Group's portfolio in Q3 2026, its #171 holding.
  • Novem Group first reported a position in United Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Novem Group's United Therapeutics position peaked at $1.38M in Q1 2026.
  • 180 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Novem Group's 13F filing for Q3 2026, filed 19 Oct 2026.